Komori
Transgenic Group (2342) · InitiativeAchieved

Elimination of Deficit Through Reduction of Share Capital and Capital Reserve and Disposition of Surplus, and Greater Flexibility in Capital Policy

First written in FY2020. 1 of 3 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2021-Q2.

3entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021-Q1 – FY2021-Q22020: 32020
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2021-Q2AchievedAnnual report

    「At the 22nd Annual General Meeting of Shareholders held on 17 June 2020, the Company resolved to reduce the amounts of capital and capital reserve and dispose of surplus. Effective 28 August 2020, it reduced capital by ¥3,434,241 thousand and capital reserve by ¥1,316,795 thousand, respectively, and transferred the same amounts to other capital surplus. In addition, pursuant to Article 452 of the Companies Act, it compensated for the deficit by transferring ¥501,821 thousand of other capital surplus to retained earnings brought forward.」

    The reduction of capital and capital reserve and the allocation of ¥501,821 thousand to compensate for the deficit became effective on 28 August 2020, completing the capital policy measures pursued since the previous fiscal year.
  2. FY2021-Q1AdvancedAnnual report

    「At the 22nd Annual General Meeting of Shareholders held on 17 June 2020, the Company obtained approval for reductions in the amounts of capital and capital reserve and for the disposition of surplus. The purpose is to compensate for the current deficit in retained earnings brought forward and strengthen the financial position, while enjoying tax benefits such as a reduction in the burden of the enterprise tax based on external standards, and to prepare for the implementation of agile and flexible capital policies and shareholder return measures in the future.」

    The Company obtained approval at the Annual General Meeting of Shareholders for the capital reduction and disposition of surplus. The plan progressed to reduce capital by ¥3,434,241 thousand and capital reserve by ¥1,316,795 thousand, and allocate ¥501,821 thousand to compensate for the deficit.
  3. FY2020First statedAnnual report

    「The purpose is to compensate for the deficit in retained earnings brought forward and strengthen the financial position, while enjoying tax benefits such as a reduction in the burden of the enterprise tax based on external standards, and to prepare for the implementation of agile and flexible capital policies and shareholder return measures in the future.」

    In May 2020, the Company resolved a plan to reduce ¥3,434,241 thousand of its ¥3,484,241 thousand capital, reduce the entire ¥1,316,795 thousand capital reserve, and allocate ¥501,821 thousand to compensate for the deficit. The effective date was scheduled for 28 August 2020.
Moved together

"Expansion into New Businesses Through M&A Centered on Capital Alliances and Business Acquisitions" moved the same way as this thread, in the same document, in 2 of its 3 moves.

2222★1234
  1. ★This thread
  2. 1Expansion into New Businesses Through M&A Centered on Capital Alliances and Business Acquisitions2×
  3. 2Raising funds through shares, convertible bonds and stock acquisition rights for growth investments, including M&A2×
  4. 3Expansion of the Advanced Medical Business, Driven by Support for Molecular Pathology and Companion Diagnostic Development2×
  5. 4Launch of Contracted COVID-19 PCR Testing2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Transgenic Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Elimination of Deficit Through Reduction of Share Capital and Capital Reserve and Disposition of Surplus, and Greater Flexibility in Capital Policy | TRANSGENIC GROUP INC. (2342) | Komori